NCT00297817 - Study of the Safety and Immune Response of Two Serogroup B Meningococcal Vaccines Administered to Healthy Adolescents | Biotech Hunter

Enrollment

203

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

April 30, 2007

Study Completion Date

April 30, 2007

Conditions

Meningococcal Disease

Interventions

BIOLOGICAL

serogroup B meningococcal vaccine

0.5mL doses in pre-filled syringes. All subjects will receive the study vaccine following a 0,2,6 vaccination schedule.

BIOLOGICAL

serogroup B meningococcal vaccine

0.5mL doses in pre-filled syringes. All subjects will receive the study vaccine following a 0,2,6 vaccination schedule.

BIOLOGICAL

serogroup B meningococcal vaccine

0.5mL doses in pre-filled syringes. All subjects will receive the placebo following a 0,2,6 vaccination schedule.

Trial Locations (8)

Atlanta

Cleveland

St Louis

Galveston

Salt Lake City

Layton

Encinitas

Seattle